ArticlePloS one2012
"One-size-fits-all"? Optimizing treatment duration for bacterial infections.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 75 citations in OpenAlex.
- A mechanism-based model of immune status effects on antibiotic PK/PD targets in bacteremia.Journal of pharmacokinetics and pharmacodynamics · 2026Article
- Triggering Toll-Like Receptor 5 Signaling During Pneumococcal Superinfection Prevents the Selection of Antibiotic Resistance.The Journal of infectious diseases · 2024Article
- Alternate Antimicrobial Therapies and Their Companion Tests.Diagnostics (Basel, Switzerland) · 2023Review
- The pharmacokinetic-pharmacodynamic modelling framework as a tool to predict drug resistance evolution.Microbiology (Reading, England) · 2023Article
- Article
- Optimising efficacy of antibiotics against systemic infection by varying dosage quantities and times.PLoS computational biology · 2020Article
- The potential negative impact of antibiotic pack on antibiotic stewardship in primary care in Switzerland: a modelling study.Antimicrobial resistance and infection control · 2020Article
- Antibiotics can be used to contain drug-resistant bacteria by maintaining sufficiently large sensitive populations.PLoS biology · 2020Article
- Effect of drug dose and timing of treatment on the emergence of drug resistanceEvolution, medicine, and public health · 2020Article
- Treatment timing shifts the benefits of short and long antibiotic treatment over infection.Evolution, medicine, and public health · 2020Article
- Diffusion-driven enhancement of the antibiotic resistance selection window.Journal of the Royal Society, Interface · 2019Article
- Evolutionary epidemiology models to predict the dynamics of antibiotic resistance.Evolutionary applications · 2019Article
- Does size matter? Addressing pack size and antibiotic duration.Australian prescriber · 2019Article
- Antimicrobial resistance (AMR) nanomachines-mechanisms for fluoroquinolone and glycopeptide recognition, efflux and/or deactivation.Biophysical reviews · 2018Review
- Evaluating drug resistance in visceral leishmaniasis: the challenges.Parasitology · 2018Review
- An ecosystem framework for understanding and treating disease.Evolution, medicine, and public health · 2018Review
- Antimicrobial drug use in food-producing animals and associated human health risks: what, and how strong, is the evidence?BMC veterinary research · 2017Review
- Article
- EMA and EFSA Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents in animal husbandry in the European Union, and the resulting impacts on food safety (RONAFA).EFSA journal. European Food Safety Authority · 2017Article
- Benefits and unintended consequences of antimicrobial de-escalation: Implications for stewardship programs.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Historically, antibiotic treatment guidelines have aimed to maximize treatment efficacy and minimize toxicity, but have not considered the evolution of antibiotic resistance. Optimizing the duration and dosing of treatment to minimize the duration of symptomatic infection and selection pressure for resistance simultaneously has the potential to extend the useful therapeutic life of these valuable life-saving drugs without compromising the interests of individual patients.Here, using mathematical models, we explore the theoretical basis for shorter durations of treatment courses, including a range of ecological dynamics of bacteria that cause infections or colonize hosts as commensals. We find that immunity is an important mediating factor in determining the need for long duration of treatment. When immunity to infection is expected, shorter durations that reduce the selection for resistance without interfering with successful clinical outcome are likely to be supported. Adjusting drug treatment strategies to account for the impact of the differences in the ecological niche occupied by commensal flora relative to invasive bacteria could be effective in delaying the spread of bacterial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.